SynapDx Raises $6M to Support Clinical Study on Autism Test | GenomeWeb

NEW YORK (GenomeWeb News) – SynapDx today announced the completion of a Series A1 financing round that brought in $6 million to support a clinical study in support of the company's test for autism spectrum disorders.

Funds from this round of financing came from North Bridge Venture Partners and General Catalyst Partners.

Southborough, Mass.-based SynapDx is developing a blood-based test that measures RNA expression to differentiate children who have a higher risk for ASDs from those who don't. Its test aims to identify children with ASD by the age of 36 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.